NAIXIONG PENG, YUEFENG CAI, DONG CHEN, LING DENG, ZEJIAN ZHANG, WEI LI^*

Oncology Research, Vol.33, No.2, pp. 347-356, 2025, DOI:10.32604/or.2024.056039 - 16 January 2025

Abstract Background: Clear cell renal carcinoma (ccRCC), the leading histological subtype of RCC, lacks any targeted therapy options. Although some studies have shown that early growth response factor 1 (EGR1) has a significant role in cancer development and progression, its role and underlying mechanisms in ccRCC remain poorly understood. Methods: The Cancer Genome Atlas (TCGA) database was utilized to examine the expression of EGR1 in ccRCC. The expression of EGR1 in 55 ccRCC tissues was evaluated using immunohistochemistry. The link between EGR1 expression and clinicopathological variables was examined through an analysis. Gain-of-function assays were employed to… More >

QI LV^1,#, GANGMIN WANG^2,#, YI HONG¹, TIANYI ZHU¹, SHUANG QIN¹, SAIFEI SUN¹, YUTING WANG¹, YAOHUA LIU¹, QING ZHANG¹, CHUNHUI MA^3,*, PEIJUN WANG^1,*

Oncology Research, Vol.33, No.2, pp. 407-420, 2025, DOI:10.32604/or.2024.047698 - 16 January 2025

Abstract Background: Sunitinib resistance is a major challenge in advanced renal cell carcinoma (RCC). Clinically, elucidating the underlying mechanisms and developing practical countermeasures for sunitinib resistance in RCC is desirable. In previous studies, we found that circAGAP1 expression was significantly upregulated in clear cell RCC (ccRCC) and was strongly associated with poor prognosis. However, the role of circAGAP1 in sunitinib resistance in ccRCC remains unclear. Methods: We used public databases for bioinformatics analysis to identify the binding targets of circAGAP1. Additionally, the effects of circAGAP1 on the proliferation, clonogenesis, apoptosis, and migration of ccRCC cells were… More > Graphic Abstract

Andrew S. Iskandar, Kevin K. Zarrabi, William J. Tester

Canadian Journal of Urology, Vol.31, No.4, pp. 11921-11930, 2024

Abstract Introduction: Renal cell carcinoma is as the most prevalent form of kidney cancer, with the clear cell subtype comprising approximately 75% of cases. The identification of predictive and prognostic biomarkers has emerged as a crucial area of research within the field. Despite advancements in treatment, metastatic renal cell carcinoma presents formidable challenges, with survival rates heavily dependent upon the optimal choice of treatment.
Materials and methods: This review summarizes the current literature regarding the prognostic and predictive value of biomarkers in patients with renal cell carcinoma. We conducted a comprehensive literature search to identify studies that reference… More >

Jacob Grassauer¹, Wesley H. Chou², Anna Geduldig¹, Jackson Schmidt², Nicholas H. Chakiryan^1,2,3,4

Canadian Journal of Urology, Vol.31, No.6, pp. 12060-12071, 2024

Abstract Introduction: It is unclear whether laterality has prognostic implications for patients with renal cell carcinoma (RCC). Some suggest that left sided tumors may have worse survival outcomes. The purpose of this study is to associate tumor characteristics and clinical outcomes with laterality in patients with RCC.
Materials and methods: Patients with RCC were identified in the National Cancer Database between 2004-2020. Patients were categorized as having either localized, regional or metastatic disease. Time-series charts were generated to demonstrate laterality differences and variance over time. Multivariable Cox proportional hazards regression was utilized to associate laterality with overall survival, stratified… More >

WEIGANG REN^1,#, JING LI^2,#, RUIJIANG ZENG^3,4, LIANG ZHU^3,4,*

BIOCELL, Vol.48, No.9, pp. 1323-1330, 2024, DOI:10.32604/biocell.2024.051747 - 04 September 2024

Abstract Background: Clear cell renal cell carcinoma (ccRCC) stands as the most prevalent form of kidney cancer, accounting for a significant proportion of malignancies affecting the kidneys. ccRCC is well known as a type of tumour with immunogenicity. Immune checkpoint inhibitors (ICIs) aim to enhance the anticancer immune response in ccRCC by blocking programmed cell death 1 ligand 1/programmed death 1 (PD-L1/PD-1) pathways. In a previous study, we showed that RING finger protein 26 (RNF26) degrades chromobox 7 (CBX7) to activate the tumor necrosis factor (TNF) in ccRCC. Methods: We analyzed The Cancer Genome Atlas (TCGA)… More > Graphic Abstract

KAIWEN TIAN^#, HANZHONG CHEN^#, QIANQIAN WANG, FENGLIAN JIANG, CHUNXIANG FENG, TENG LI, XIAOYONG PU, YANLIN TANG^*, JIUMIN LIU^*

BIOCELL, Vol.48, No.5, pp. 817-834, 2024, DOI:10.32604/biocell.2024.048737 - 06 May 2024

Abstract Background: The incidence of clear cell renal cell carcinoma (ccRCC) is globally high; however, despite the introduction of innovative drug therapies, there remains a lack of effective biomarkers for evaluating treatment response. Recently, Caspase recruiting domain-containing protein 11 (CARD11) has garnered attention due to its significant association with tumor development and the immune system. Methods: The expression of CARD11 mRNA and protein in ccRCC were analyzed by public database and immunohistochemistry. The focus of this study is on the epigenomic modifications of CARD11, its expression of ccRCC immunophenotype, and its correlation with response to immunotherapy… More > Graphic Abstract

Kun Yang^1,2,3, Shilong Chang¹, Yucheng Wang¹, Minghui Wang¹, Jiahui Yang¹, Shuang Liu^1,2,3, Kun Liu^1,2,3, Linyan Xue^1,2,3,*

CMC-Computers, Materials & Continua, Vol.78, No.1, pp. 393-410, 2024, DOI:10.32604/cmc.2023.044994 - 30 January 2024

Abstract Clear cell renal cell carcinoma (ccRCC) represents the most frequent form of renal cell carcinoma (RCC), and accurate International Society of Urological Pathology (ISUP) grading is crucial for prognosis and treatment selection. This study presents a new deep network called Multi-scale Fusion Network (MsfNet), which aims to enhance the automatic ISUP grade of ccRCC with digital histopathology pathology images. The MsfNet overcomes the limitations of traditional ResNet50 by multi-scale information fusion and dynamic allocation of channel quantity. The model was trained and tested using 90 Hematoxylin and Eosin (H&E) stained whole slide images (WSIs), which… More >

Erin Howells¹, Lucas Wigston², Gavin Mackie¹, Ben Tran³, Louise Nott⁴

Canadian Journal of Urology, Vol.30, No.3, pp. 11558-11561, 2023

Abstract Fumarate hydratase deficient (FHdef) renal cell carcinoma (RCC) is rare, highly aggressive and is believed to arise mostly in the setting of hereditary leiomyomatosis RCC (HLRCC) syndrome with a germline mutation of fumarate hydratase (FH) gene. There is currently little evidence regarding the most effective systemic treatment for advanced FHdef RCC. We present three cases of metastatic FHdef RCC, all achieving tumor response with combination immunotherapy ipilimumab and nivolumab (Ipi/Nivo). A 50-year-old male, a 27-year-old male and a 48-year-old female. The clinical features, diagnosis and medical imaging are reviewed. More >

RENLONG ZHOU^1,2,#, SHUANG LI^3,#, XILIN XIAO^1,*

BIOCELL, Vol.47, No.11, pp. 2397-2408, 2023, DOI:10.32604/biocell.2023.030281 - 27 November 2023

Abstract Background: In many cancer types, aryl hydrocarbon receptor nuclear translocator 2 (ARNT2) has been found to be associated with tumor cell proliferation and prognosis. However, the role of ARNT2 in clear cell renal cell carcinoma (ccRCC) has not been completely elucidated. In this study, the potential role of ARNT2 in ccRCC development was characterized. Methods: A pan-cancer dataset (TCGA-TARGET-GTEx) was accessed from UCSC Xena Data Browser. ARNT2 expression in normal and tumor samples was compared. Univariate Cox regression was performed to evaluate the prognostic value of ARNT2. Single sample gene set enrichment analysis (ssGSEA) was… More >

WENFEI GE^1,#, SHIYAN SONG^1,#, XIAOCHEN QI^1,#, FENG CHEN^1,#, XIANGYU CHE¹, YONGHAO SUN¹, JIN WANG¹, XIAOWEI LI², NANA LIU³, QIFEI WANG^1,*, GUANGZHEN WU^1,*

Oncology Research, Vol.31, No.3, pp. 255-270, 2023, DOI:10.32604/or.2023.027942 - 22 May 2023

Abstract As a common tumor of the urinary system, the morbidity and mortality related to renal carcinoma, are increasing annually. Clear cell renal cell carcinoma (CCRCC) is the most common subtype of renal cell carcinoma, accounting for approximately 75% of the total number of patients with renal cell carcinoma. Currently, the clinical treatment of ccRCC involves targeted therapy, immunotherapy, and a combination of the two. In immunotherapy, PD-1/PD-L1 blocking of activated T cells to kill cancer cells is the most common treatment. However, as treatment progresses, some patients gradually develop resistance to immunotherapy. Meanwhile, other patients More > Graphic Abstract